KRAS G12V TCR-T cells

KRAS G12V TCR-T cells are autologous or allogeneic adoptive cell therapies in which patient or donor-derived T lymphocytes are genetically engineered to express a high-affinity, tumor-specific T cell receptor (TCR) that recognizes the mutant KRAS G12V neoantigen presented by specific human leukocyte antigen (HLA) molecules on tumor cells. The therapy is designed to selectively target and kill cancer cells harboring the oncogenic KRAS G12V mutation while sparing normal tissues. These engineered TCRs have demonstrated potent cytokine secretion and cytotoxicity against various solid tumors expressing the mutation in preclinical models. Some constructs also include additional modifications such as co-expression of CD8ab for enhanced CD4+ activity and a FAS-41BB switch receptor to improve resistance to immunosuppressive mechanisms within the tumor microenvironment[2][3][5]. The primary indication is for solid tumors with confirmed KRAS G12V mutations, including non-small cell lung cancer (NSCLC), colorectal cancer, and pancreatic ductal adenocarcinoma[4].

Other names

KRAS G12V-specific TCR-T cellsKRAS-G12V neoantigen specific T cell receptor engineered T cellsKRAS-G-12V neoantigen specific T cell receptor engineered T cellsKRAS-G 12V neoantigen specific T cell receptor engineered T cellsA11-KRAS G12V/CD8ab/FAS-41BB switch receptor engineered T cells